SCHEMBL4385279

SCHEMBL4385279

COc1ncccc1CON=C1CCN(S(=O)(=O)c2ccc(OC(F)(F)F)cc2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.44
PRCP P42785 2/20 0.42
MEN1 O00255 6/20 0.41
KMT2A Q03164 6/20 0.41
GBA1 P04062 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
NPC1 O15118 1/20 0.37
PKM P14618 1/20 0.37
PKLR P30613 1/20 0.37
RAB9A P51151 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4386428 0.87 PRCP (0.46) HSD11B1PRCPMEN1KMT2AGBA1
SCHEMBL4384729 0.83 PRCP (0.44) HSD11B1PRCPMEN1KMT2AGBA1
SCHEMBL4383891 0.83 PRCP (0.47) HSD11B1PRCPMEN1KMT2AGBA1
SCHEMBL4379123 0.82 PRCP (0.47) HSD11B1PRCPMEN1KMT2AGBA1
SCHEMBL4390793 0.81 MEN1 (0.45) PRCPMEN1KMT2AGBA1CYP2C9
SCHEMBL4392776 0.81 HSD11B1 (0.41) HSD11B1PRCPMEN1KMT2AHDAC3
SCHEMBL4388852 0.81 MEN1 (0.41) MEN1KMT2AGBA1CYP2C9LMNA
SCHEMBL4385376 0.80 EGLN1 (0.38) HSD11B1PRCPMEN1KMT2AHDAC3
SCHEMBL4382834 0.80 HDAC3 (0.42) HSD11B1PRCPMEN1KMT2AGBA1
SCHEMBL4383823 0.80 GBA1 (0.46) HSD11B1MEN1KMT2AGBA1CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 US disclosed
EP-2040698-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2009-04-01 EP disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 HSD11B1 1648/4885PRCP 3210/4885MEN1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.